Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20547754
Alan JK, et al. (2010) Regulation of the Rho family small GTPase Wrch-1/RhoU by C-terminal tyrosine phosphorylation requires Src. Mol Cell Biol 30, 4324-38 20547754
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T423-p - PAK1 (human)
Modsite: PEQSkRstMVGtPYW SwissProt Entrez-Gene
Orthologous residues
PAK1 (human): T423‑p, PAK1 (mouse): T423‑p, PAK1 (rat): T422‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RHOU (human) decrease RHOU Y254E mutant
RHOU (human) increase RHOU wt or Y254F mutant

Y402-p - Pyk2 (human)
Modsite: CsIEsDIyAEIPDEt SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y402‑p, Pyk2 iso2 (human): Y402‑p, Pyk2 (mouse): Y402‑p, Pyk2 (rat): Y402‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RHOU (human) decrease RHOU Y254E mutant
RHOU (human) increase RHOU wt or Y254F mutant

Y254-p - RHOU (human)
Modsite: SkSWWKKyCCFV___ SwissProt Entrez-Gene
Orthologous residues
RHOU (human): Y254‑p, RHOU (mouse): Y257‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  MDCKII (epithelial), MEF (fibroblast), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) genetic knockout/knockin of upstream enzyme, pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, transfection of inactive enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
SU6656 serum inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation
Effect of modification (process):  cell growth, altered, cytoskeletal reorganization
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PAK1 (human) PBD Disrupts microscopy-colocalization